Janus Henderson Group PLC Entrada Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $194 Billion
- Q2 2025
A detailed history of Janus Henderson Group PLC transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 1,521,281 shares of TRDA stock, worth $10.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,521,281
Previous 2,121,654
28.3%
Holding current value
$10.5 Million
Previous $19.2 Million
46.7%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding TRDA
# of Institutions
106Shares Held
28.7MCall Options Held
15.7KPut Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$33.6 Million0.33% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$30.2 Million67.92% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.31MShares$29.7 Million19.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.57MShares$17.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$11.7 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $216M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...